Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment
Public ClinicalTrials.gov record NCT00422981. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Effect on Cognitive Function of AL-108 After 12 Weeks of Intranasal Administration in Subjects With Mild Cognitive Impairment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).
Study identification
- NCT ID
- NCT00422981
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 144 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 55 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2006
- Primary completion
- Dec 31, 2007
- Completion
- Dec 31, 2007
- Last update posted
- Oct 23, 2012
2007 – 2008
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pivotal Research | Peoria | Arizona | 85381 | — |
| Collaborative Neuroscience Network | Garden Grove | California | 92845 | — |
| Synergy Research | National City | California | 91950 | — |
| Pacific Research Network, Inc | San Diego | California | 92103 | — |
| Meridien Research | Brooksville | Florida | 34613 | — |
| Clinical Neuroscience Solutions, Inc. | Jacksonville | Florida | 32216 | — |
| Clinical Neuroscience Solutions | Orlando | Florida | 32806 | — |
| Meridien Research | Tampa | Florida | 33606 | — |
| Stedman Clinical Trials | Tampa | Florida | 33613 | — |
| Clinical Research Center of Indian River Medical Center | Vero Beach | Florida | 32960 | — |
| Comprehensive Neuroscience | Hoffman Estates | Illinois | 60194 | — |
| The Memory Enhancement Center of America | Long Branch | New Jersey | 07740 | — |
| SPRI Clinical trials | Brooklyn | New York | 11235 | — |
| Memory Assessment and Research Services | Wilmington | North Carolina | 28405 | — |
| Neurology & Neuroscience Center of Ohio | Toledo | Ohio | 43623 | — |
| Clinical Neuroscience Solutions, Inc | Memphis | Tennessee | 38119 | — |
| Senior Adults Speciality Research | Austin | Texas | 78757 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00422981, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 23, 2012 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00422981 live on ClinicalTrials.gov.